AL
Alkem Labs
ALKEM.NS·NSEMumbai INFounded 197315,000 employees
Mid CappharmaPublicInfectious DiseaseOncology
Platform: Anti-infective
Market Cap
$6B
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (ALKEM.NS)
Loading ALKEM.NS stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sototenlimab | ALK-5522 | Preclinical | 2 | BCMA | PBC | ||
| Talafutibatinib | ALK-7461 | Phase 3 | 2 | TROP-2 | PompeADPKD | ||
| Zoriratamab | ALK-1110 | Preclinical | 1 | BET | TTR Amyloidosis | ||
| ALK-3993 | ALK-3993 | Phase 3 | 1 | SOS1 | MigraineNarcolepsy |
SEC Filings & Financial Documents
SEC filings are not available for NSE-listed companies.
Alkem Labs trades on NSE (IN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (3)